{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:06:31Z","timestamp":1790845591643,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"7-8","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T00:00:00Z","timestamp":1751155200000},"content-version":"am","delay-in-days":363,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.bulcan.2022.09.011","type":"journal-article","created":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T02:23:13Z","timestamp":1668046993000},"page":"663-674","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Imagerie des cancers et pr\u00e9vention de l\u2019insuffisance r\u00e9nale"],"prefix":"10.1016","volume":"111","author":[{"given":"Sylvain","family":"Bodard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dris","family":"Kharroubi-Lakouas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Guinebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Dariane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Gillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Sakhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Ferriere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Delaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-Olivier","family":"Timsit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Correas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"H\u00e9l\u00e9non","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idris","family":"Boudhabhay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2022.09.011_bib0290","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.2215\/CJN.09011010","article-title":"Cancer-specific mortality in chronic kidney disease: longitudinal follow-up of a large cohort","volume":"6","author":"Weng","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.bulcan.2022.09.011_bib0295","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.nephro.2019.04.005","article-title":"Premature immune senescence and chronic kidney disease: update and perspectives","volume":"16","author":"Cr\u00e9pin","year":"2020","journal-title":"Nephrol Ther"},{"key":"10.1016\/j.bulcan.2022.09.011_bib0300","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1200\/JCO.19.02138","article-title":"Improving cancer care for patients with chronic kidney disease","volume":"38","author":"Sprangers","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2022.09.011_bib0305","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.0954-6820.1954.tb18632.x","article-title":"Acute anuria following intravenous pyelography in a patient with myelomatosis","volume":"150","author":"Bartels","year":"1954","journal-title":"Acta Med Scand"},{"key":"10.1016\/j.bulcan.2022.09.011_bib0310","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1053\/ajkd.2002.32766","article-title":"Hospital-acquired renal insufficiency","volume":"39","author":"Nash","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.bulcan.2022.09.011_bib0315","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/MNH.0000000000000562","article-title":"Preventing a nonexistent entity: the curious case of contrast and acute kidney injury","volume":"29","author":"Hiremath","year":"2020","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.bulcan.2022.09.011_bib0320","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1053\/j.ajkd.2019.05.022","article-title":"The Controversy of Contrast-Induced Nephropathy With Intravenous Contrast: What Is the Risk\u00a0?","volume":"75","author":"Rudnick","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.bulcan.2022.09.011_bib0325","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/ndt\/gfaa183","article-title":"Contrast and acute kidney injury: what is left to enhance?","volume":"37","author":"Hiremath","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.bulcan.2022.09.011_bib0330","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1007\/s00330-017-5247-4","article-title":"Post-contrast acute kidney injury. Part 2: risk stratification, role of hydration and other prophylactic measures, patients taking metformin and chronic dialysis patients","volume":"28","author":"van der Molen","year":"2018","journal-title":"Eur Radiol"},{"key":"10.1016\/j.bulcan.2022.09.011_bib0335","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.nephro.2020.10.011","article-title":"ESUR recommendations on the use of contrast media: practice survey, review and commentary by CJN, FIRN and SFNDT","volume":"17","author":"de Laforcade","year":"2021","journal-title":"Nephrol Ther"},{"key":"10.1016\/j.bulcan.2022.09.011_bib0340","doi-asserted-by":"crossref","first-page":"166","DOI":"10.17533\/udea.iatreia.4478","article-title":"Nefropat\u00eda inducida por medios de contraste radiol\u00f3gico yodados","volume":"21","author":"Balparda Arias","year":"2008","journal-title":"Iatreia"},{"key":"10.1016\/j.bulcan.2022.09.011_bib0345","doi-asserted-by":"crossref","first-page":"e387","DOI":"10.1016\/j.ejrad.2013.04.029","article-title":"Contrast induced nephropathy in patients undergoing intravenous (IV) contrast enhanced computed tomography (CECT) and the relationship with risk factors: a meta-analysis","volume":"82","author":"Moos","year":"2013","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.bulcan.2022.09.011_bib0350","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1016\/j.ejrad.2011.11.020","article-title":"Meta-analysis: serum creatinine changes following contrast enhanced CT imaging","volume":"81","author":"Kooiman","year":"2012","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.bulcan.2022.09.011_bib0355","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000484970","article-title":"Acute kidney injury in cancer patients","volume":"193","author":"Gallieni","year":"2018","journal-title":"Contrib Nephrol"},{"key":"10.1016\/j.bulcan.2022.09.011_bib0360","doi-asserted-by":"crossref","first-page":"8736163","DOI":"10.1155\/2019\/8736163","article-title":"Risk prediction for contrast-induced nephropathy in cancer patients undergoing computed tomography under preventive measures","volume":"2019","author":"Jeon","year":"2019","journal-title":"J Oncol"},{"key":"10.1016\/j.bulcan.2022.09.011_bib0365","doi-asserted-by":"crossref","first-page":"e13351","DOI":"10.1111\/ecc.13351","article-title":"Administration of iodinated contrast: what is the risk in cancer patients?","volume":"30","author":"Gonz\u00e1lez Cervantes","year":"2021","journal-title":"Eur J Cancer Care (Engl)"},{"key":"10.1016\/j.bulcan.2022.09.011_bib0370","doi-asserted-by":"crossref","DOI":"10.1159\/000339789","article-title":"KDIGO clinical practice guidelines for acute kidney injury","volume":"120","author":"Khwaja","year":"2012","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.bulcan.2022.09.011_bib0375","unstructured":"Agent de Contraste - CIRTACI n.d. http:\/\/www.sfrnet.org\/sfr\/societe\/5-groupes-de-travail\/qualite-securite-gestion-des-risques\/agents-de-contraste-cirtaci\/index.phtml (accessed May 31, 2022)."},{"key":"10.1016\/j.bulcan.2022.09.011_bib0380","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1148\/radiol.13122276","article-title":"Contrast material-induced nephrotoxicity and intravenous low-osmolality iodinated contrast material: risk stratification by using estimated glomerular filtration rate","volume":"268","author":"Davenport","year":"2013","journal-title":"Radiology"},{"key":"10.1016\/j.bulcan.2022.09.011_bib0385","first-page":"65","article-title":"Determination of serum creatinine prior to iodinated contrast media: is it necessary in all patients?","volume":"4","author":"Choyke","year":"1998","journal-title":"Tech Urol"},{"key":"10.1016\/j.bulcan.2022.09.011_bib0390","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1148\/radiology.216.2.r00au23481","article-title":"Are screening serum creatinine levels necessary prior to outpatient CT examinations?","volume":"216","author":"Tippins","year":"2000","journal-title":"Radiology"},{"key":"10.1016\/j.bulcan.2022.09.011_bib0395","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1007\/s00330-013-3065-x","article-title":"Can a structured questionnaire identify patients with reduced renal function?","volume":"24","author":"Azzouz","year":"2014","journal-title":"Eur Radiol"},{"key":"10.1016\/j.bulcan.2022.09.011_bib0400","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.ejrad.2015.04.001","article-title":"Screening for impaired renal function in outpatients before iodinated contrast injection: Comparing the Choyke questionnaire with a rapid point-of-care-test","volume":"84","author":"Too","year":"2015","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.bulcan.2022.09.011_bib0405","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1177\/0284185114533244","article-title":"Serum creatinine measurements: evaluation of a questionnaire according to the ESUR guidelines","volume":"56","author":"Z\u00e4hringer","year":"2015","journal-title":"Acta Radiol"},{"key":"10.1016\/j.bulcan.2022.09.011_bib0410","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.acra.2012.04.016","article-title":"Comparison of the sensitivity of a pre-MRI questionnaire and point of care eGFR testing for detection of impaired renal function","volume":"19","author":"Chang","year":"2012","journal-title":"Acad Radiol"},{"key":"10.1016\/j.bulcan.2022.09.011_bib0415","first-page":"271","article-title":"Cost of screening strategies for kidney disease before intravenous contrast administration","volume":"72","author":"Moos","year":"2014","journal-title":"Neth J Med"},{"key":"10.1016\/j.bulcan.2022.09.011_bib0420","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/JU.0000000000001912","article-title":"Renal mass and localized renal cancer: evaluation management, and follow-up: aua guideline: Part II","volume":"206","author":"Campbell","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.bulcan.2022.09.011_bib0425","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.2169\/internalmedicine.53.1853","article-title":"Remedial hydration reduces the incidence of contrast-induced nephropathy and short-term adverse events in patients with ST-segment elevation myocardial infarction: a single-center, randomized trial","volume":"53","author":"Luo","year":"2014","journal-title":"Intern Med"},{"key":"10.1016\/j.bulcan.2022.09.011_bib0430","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/S0140-6736(17)30057-0","article-title":"Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial","volume":"389","author":"Nijssen","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.bulcan.2022.09.011_bib0435","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1007\/s00330-017-5246-5","article-title":"Post-contrast acute kidney injury - Part 1: definition, clinical features, incidence, role of contrast medium and risk factors: recommendations for updated esur contrast medium safety committee guidelines","volume":"28","author":"van der Molen","year":"2018","journal-title":"Eur Radiol"},{"key":"10.1016\/j.bulcan.2022.09.011_bib0440","doi-asserted-by":"crossref","first-page":"e60009","DOI":"10.1371\/journal.pone.0060009","article-title":"Prevention of contrast-induced acute kidney injury: is simple oral hydration similar to intravenous? A systematic review of the evidence","volume":"8","author":"Hiremath","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bulcan.2022.09.011_bib0445","doi-asserted-by":"crossref","first-page":"618","DOI":"10.4103\/1947-2714.147977","article-title":"Oral hydration for prevention of contrast-induced acute kidney injury in elective radiological procedures: a systematic review and meta-analysis of randomized controlled trials","volume":"6","author":"Cheungpasitporn","year":"2014","journal-title":"N Am J Med Sci"},{"key":"10.1016\/j.bulcan.2022.09.011_bib0450","doi-asserted-by":"crossref","first-page":"e000317","DOI":"10.1136\/openhrt-2015-000317","article-title":"Systematic oral hydration with water is similar to parenteral hydration for prevention of contrast-induced nephropathy: an updated meta-analysis of randomised clinical data","volume":"2","author":"Agarwal","year":"2015","journal-title":"Open Heart"},{"key":"10.1016\/j.bulcan.2022.09.011_bib0455","unstructured":"Richtlijnen | Nederlandse Federatie voor Nefrologie n.d. https:\/\/www.nefro.nl\/richtlijnen (accessed May 31, 2022)."},{"key":"10.1016\/j.bulcan.2022.09.011_bib0460","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1517\/14740338.4.4.689","article-title":"Drug-induced nephropathy: an update","volume":"4","author":"Perazella","year":"2005","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.bulcan.2022.09.011_bib0465","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1007\/s00330-017-5247-4","article-title":"Post-contrast acute kidney injury. Part 2: risk stratification, role of hydration and other prophylactic measures, patients taking metformin and chronic dialysis patients: Recommendations for updated ESUR Contrast Medium Safety Committee guidelines","volume":"28","author":"van der Molen","year":"2018","journal-title":"Eur Radiol"},{"key":"10.1016\/j.bulcan.2022.09.011_bib0470","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc14-2441","article-title":"Management of hyperglycemia in type 2\u00a0diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"38","author":"Inzucchi","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bulcan.2022.09.011_bib0475","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1001\/jama.2014.15298","article-title":"Metformin in patients with type 2\u00a0diabetes and kidney disease: a systematic review","volume":"312","author":"Inzucchi","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.bulcan.2022.09.011_bib0480","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1177\/1060028013505428","article-title":"Unleash metformin: reconsideration of the contraindication in patients with renal impairment","volume":"47","author":"Lu","year":"2013","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.bulcan.2022.09.011_bib0485","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.2337\/dc14-0464","article-title":"Incidence of lactic acidosis in patients with type 2\u00a0diabetes with and without renal impairment treated with metformin: a retrospective cohort study","volume":"37","author":"Richy","year":"2014","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.bulcan.2022.09.011_bib0490","first-page":"CD002967","article-title":"Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus","volume":"2010","author":"Salpeter","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.bulcan.2022.09.011_bib0495","unstructured":"Research C for DE and. FDA Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. FDA 2019."},{"key":"10.1016\/j.bulcan.2022.09.011_bib0500","unstructured":"Flobbe K. Richtlijn Veilig Gebruik van Contrastmiddelen- deel 1 (Full English) 2017. https:\/\/www.radiologen.nl\/secties\/nvvr\/documenten\/richtlijn-veilig-gebruik-van-contrastmiddelen-deel-1-full-english (accessed May 31, 2022)."},{"key":"10.1016\/j.bulcan.2022.09.011_bib0505","unstructured":"Masson E. \u00c9chographie de contraste: les applications r\u00e9nales. EM-Consulte n.d. https:\/\/www.em-consulte.com\/article\/121492\/echographie-de-contraste-les-applications-renales (accessed May 31, 2022)."},{"key":"10.1016\/j.bulcan.2022.09.011_bib0510","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/00004424-199508000-00001","article-title":"BR1: a new ultrasonographic contrast agent based on sulfur hexafluoride-filled microbubbles","volume":"30","author":"Schneider","year":"1995","journal-title":"Invest Radiol"},{"key":"10.1016\/j.bulcan.2022.09.011_bib0515","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1148\/radiology.176.3.1697079","article-title":"Renal masses: characterization with Doppler US","volume":"176","author":"Kier","year":"1990","journal-title":"Radiology"},{"key":"10.1016\/j.bulcan.2022.09.011_bib0520","first-page":"50","article-title":"Color Doppler flow imaging of renal disease. Value of a new intravenous contrast agent: SH U 508\u00a0A (Levovist)","volume":"87","author":"Filippone","year":"1994","journal-title":"Radiol Med"},{"key":"10.1016\/j.bulcan.2022.09.011_bib0525","doi-asserted-by":"crossref","first-page":"581","DOI":"10.7863\/jum.1999.18.9.581","article-title":"Contrast-enhanced power Doppler sonography for the differentiation of cystic renal lesions: preliminary study","volume":"18","author":"Kim","year":"1999","journal-title":"J Ultrasound Med"},{"key":"10.1016\/j.bulcan.2022.09.011_bib0530","unstructured":"Masson E. Tomodensitom\u00e9trie spectrale: de la double \u00e9nergie \u00e0 la multi\u00e9nergie. EM-Consulte n.d. https:\/\/www.em-consulte.com\/article\/1268634\/tomodensitometrie-spectrale\u00a0-de-la-double-energie- (accessed May 31, 2022)."},{"key":"10.1016\/j.bulcan.2022.09.011_bib0535","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.2214\/AJR.12.9116","article-title":"Dual-energy CT: general principles","volume":"199","author":"Johnson","year":"2012","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.bulcan.2022.09.011_bib0540","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1148\/radiol.12120195","article-title":"Spectral optimization of chest CT angiography with reduced iodine load: experience in 80\u00a0patients evaluated with dual-source, dual-energy CT","volume":"267","author":"Delesalle","year":"2013","journal-title":"Radiology"},{"key":"10.1016\/j.bulcan.2022.09.011_bib0545","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1148\/rg.2016150185","article-title":"Dual-Energy Spectral CT: various clinical vascular applications","volume":"36","author":"Machida","year":"2016","journal-title":"Radiographics"},{"key":"10.1016\/j.bulcan.2022.09.011_bib0550","doi-asserted-by":"crossref","first-page":"108756","DOI":"10.1016\/j.ejrad.2019.108756","article-title":"Venous-phase chest CT with reduced contrast medium dose: utilization of spectral low keV monoenergetic images improves image quality","volume":"122","author":"Hickethier","year":"2020","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.bulcan.2022.09.011_bib0555","first-page":"6972","article-title":"Diagnostic protocols in oncology: workup and treatment planning. Part 1: the optimitation of CT protocol","volume":"25","author":"Granata","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.bulcan.2022.09.011_bib0560","first-page":"670","article-title":"A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): nontoxic tracer for rapid tumor detection","volume":"21","author":"Som","year":"1980","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bulcan.2022.09.011_bib0565","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fonc.2017.00155","article-title":"Impact of Renal Failure on F18-FDG PET\/CT Scans","volume":"7","author":"Kode","year":"2017","journal-title":"Front Oncol"},{"key":"10.1016\/j.bulcan.2022.09.011_bib0285","first-page":"204","article-title":"Comparison of FDG-PET\/CT images between chronic renal failure patients on hemodialysis and controls","volume":"5","author":"Toriihara","year":"2015","journal-title":"Am J Nucl Med Mol Imaging"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455122003927?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455122003927?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T02:02:55Z","timestamp":1719712975000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455122003927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":57,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0007455122003927"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2022.09.011","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Imagerie des cancers et pr\u00e9vention de l\u2019insuffisance r\u00e9nale","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2022.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}